novo nordisk semaglutide alzheimer trial evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of in early-stage symptomatic Alzheimer's disease | Alzheimer's Research & Therapy Semaglutide's Setback in Alzheimer Disease

Lean muscle preservation matters because it protects your metabolic rate from the decline that typically occurs during weight loss

10.4103/NRR.NRR-D-24-00112 125 ZhuX.LuH.JiaH.WeiX.XueJ.LiW.et al (2025)

But really, these medications are intended and approved for long-term, potentially forever, use

More effective medications produce larger weight loss during treatment and larger potential regain after stopping

Daily Dots adhesive patches are designed for comfort, convenience, and discretion

GLP-1RA is widely used as a treatment for T2D, and in addition to improving glycemic control, it has been suggested that it may act on multiple mechanisms related to the pathophysiology of AD, including neuroprotective, anti-inflammatory, and antioxidant effects